Polymer Drugs in the Clinical Stage pp 59-67 | Cite as
Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C
Chapter
Keywords
Chronic Hepatitis Sustained Virological Response Vinyl Sulfone Unmodified Protein Succinimidyl Carbonate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Sharara, A.I., Hunt, C.M., et al., 1996, Hepatitis C. Ann Intern Med 125:658–68.PubMedGoogle Scholar
- 2.Koziel, M.J., 1996, Immunology of viral hepatitis. Am J Med 100:98–109.CrossRefPubMedGoogle Scholar
- 3.Kiyasu, P.K. and Caldwell, S.H., 1993, Diagnosis and treatment of the major hepatotropic viruses. Am J Med Sci 306: 248–61.PubMedGoogle Scholar
- 4.Iwarson, S., Norkraus, G. et al., 1995, Hepatitis C: natural history of a unique infection. Clin Infect Dis 20: 1361–70.PubMedGoogle Scholar
- 5.Alter, M., 1997, Epidemiology of hepatitis C. Hepatology 26:(3 Suppl 1): 625–655.Google Scholar
- 6.Davis, G.L., 2000, Current therapy for chronic hepatitis C. Gastroenterol 118(Suppl 1): S104–S114.Google Scholar
- 7.Lawrence, S.P., 2000, Advances in the treatment of hepatitis C. In Advances in Internal Medicine. Mosby, St. Louis.Google Scholar
- 8.Hoofnagle, J.H. and di Bisceglie, A.M., 1997, The treatment of chronic viral hepatitis. N Engl J Med 336: 347–56.CrossRefPubMedGoogle Scholar
- 9.McHutchinson, J.G., Gordon, S.C., et. al., 1998, Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485–92.Google Scholar
- 10.Wills, R.J., 1990, Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390–399.PubMedGoogle Scholar
- 11.Bocci, V., Pacini, A. et. al., 1981, Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1: 347–52.PubMedGoogle Scholar
- 12.Zeuzem, S., Herrmann, E. et. al., 2001, Viral kinetics with chronic hepatitis C patients treated with standard or peginterferon alfa-2a. Gastroenterol 120: 1438–1447.Google Scholar
- 13.Lam, N.P. Neumann, A.U. et. al., 1997, Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226–31.PubMedGoogle Scholar
- 14.Zhi, J., Teller, S.B. et al., 1995, Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2b given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 35: 281–4.PubMedGoogle Scholar
- 15.Harris, J.M., Martin, N.E., et. al., 2001, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539–51.PubMedGoogle Scholar
- 16.Yamaoka, T., Tabata, Y., et. al., 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm Sci 83: 601–6.PubMedGoogle Scholar
- 17.Fung, W.-J., Porter, J.E., et. al., 1997, Strategies for the preparation and characterization of polyethylene glycol vinyl sulfone. Polymers Preprint: 565–66.Google Scholar
- 18.Nieforth, K.A., Nadeau, R., et. al., 1996, Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59: 636–46.CrossRefPubMedGoogle Scholar
- 19.Xu, Z.-X., Patel, I., et al., 1998, Single-dose safety, tolerability and pharmacokinetics of PEG-FIN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 28(Suppl): 702.Google Scholar
- 20.Bailon, P., Palleroni, A., et al., 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12: 195–202.CrossRefGoogle Scholar
- 21.Bailon, P., Spence, C., et al., 1999, Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antiviral Therapy 4(Suppl 4): 27.Google Scholar
- 22.Harris, N.J., Veronese, F.M., et al., 1999, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces. US Patent & Trademark Office, USA.Google Scholar
- 23.Algranati, N.E., Sy, S., et. al., 1999, A branched methoxy 40 kDa, polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-IFN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40: 190.Google Scholar
- 24.Modi, M.W., Fried, M.W., et. al., 2000, The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis patients after multiple dosing. Hepatology 32 (4 Pt 2 of 2): 394A.Google Scholar
- 25.Zeuzem, S., Feinman, S.V., et al., 2000, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–72.CrossRefPubMedGoogle Scholar
- 26.Heathcote, E.J., Shiftman, M.J., et. al., 2000, Peginterferon alfa-2a in patieints with chronic hepatitis C and cirrhosis. N Engl J Med 345: 1673–80.Google Scholar
Copyright information
© Kluwer Academic Publishers 2004